See what’s new.
GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
GeneVentiv Therapeutics, a Raleigh-based gene therapy company, has taken an exclusive license to Pompe disease gene editing technology developed in the lab of Professor Dwight Koeberl (Pediatrics, SOM).
VQ Biomedical secures $5M, including a seed round led by Harbright, WIN, and DCP
VQ Biomedical is a Duke University start-up and DCP portfolio company resulting from the collaboration Duke clinicians and engineers.
Durham agtech startup Avalo secures $11M in funding
Avalo is a Duke agtech start-up based on technology developed by former postdoc Mariano Alvarez (Biology, Trinity) and Professor Cynthia Rudin (CS, Trinity).
Duke University ranks 24th worldwide for patents granted to academic institutions
Duke researchers are pioneering inventors and Duke is successfully commercializing these inventions for the benefit of the public.
Donald Patrick McDonnell, PhD, Wins 2025 Baxter Prize for Entrepreneurship
Professor Donald McDonnell (PCB, SOM) is a serial inventor with multiple commercialized technologies, including FDA-approved breast cancer drug ORSERDU.
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.
Lumotive Raises $45 Million to Expand Sales of Programmable Optical Semiconductors
Lumotive is a metamaterials start-up spun out of the labs of Professor David Smith and Associate Professor Maiken Mikkelsen (ECE, Pratt). Mikkelsen's former postdoc Gleb Akselrod is the founder and CTO.
Dr. Jim Flatt Announced as New CEO of DMC Biotechnologies
DMC Technologies is a Duke start-up commercializing sustainable chemistry technology out of the lab of Associate Professor Michael Lynch (BME, Pratt).
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).